Dr. Sciortino is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3001 W Dr Martin Luther King Jr Blvd
Tampa, FL 33607Phone+1 813-321-6589Fax+1 813-321-6590
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1983 - 1984
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1981 - 1983- Icahn School of Medicine at Mount Sinai (Bronx)Residency, Internal Medicine, 1978 - 1981
Universidad Autonoma de GuadalajaraClass of 1977
Certifications & Licensure
FL State Medical License 2012 - 2026
IN State Medical License 1984 - 2019
HI State Medical License 2016 - 2018
NY State Medical License 1978 - 2017
MO State Medical License Active through 2013
PA State Medical License Active through 2012- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 11 citationsLong-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.Nicholas W. Choong, Ann M. Mauer, Daniel Haraf, Mark K. Ferguson, Alan Sandler
Medical Oncology. 2011-12-01 - 29 citationsPhase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancerSridhar Mani, John W. Kugler, James A. Knost, David F. Sciortino, Joseph Gibbons
Investigational New Drugs. 1998-01-01 - 23 citationsPhase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinomaSridhar Mani, David F. Sciortino, Brian L. Samuels, Rose Arrietta, Richard L. Schilsky
Investigational New Drugs. 1999-01-01
Press Mentions
MoCannTrade Announces New Board LeadershipJuly 14th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
